Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management

It is well known that hepatitis B virus reactivation (HBVr) can occur among patients undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in patients undergoing immunosuppressive treatments is a multidimensional process, which includes conducting an accurate clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Zannella, Alessandra, Marignani, Massimo, Begini, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784078/
https://www.ncbi.nlm.nih.gov/pubmed/31540124
http://dx.doi.org/10.3390/v11090858

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784078/
https://www.ncbi.nlm.nih.gov/pubmed/31540124
http://dx.doi.org/10.3390/v11090858

Ejemplares similares